ethyl 3-(benzyloxy)-1H-pyrazole-4-carboxylate | 478968-83-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: ethyl 3-(benzyloxy)-1H-pyrazole-4-carboxylate
• 英文别名: 3-benzyloxy-1H-pyrazole-4-carboxylic acid ethyl ester；ethyl 5-phenylmethoxy-1H-pyrazole-4-carboxylate
• CAS: 478968-83-1
• 化学式: C₁₃H₁₄N₂O₃
• 分子量: 246.266
• InChiKey: RMAVFUHHCXYBCE-UHFFFAOYSA-N

物化性质

• 沸点：
  436.3±30.0 °C(Predicted)
• 密度：
  1.230±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  64.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 3-(benzyloxy)-1H-pyrazole-4-carboxylate 在 sodium hydroxide 、 sodium hydride 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 2.5h， 生成 3-(benzyloxy)-1-methyl-1H-pyrazole-4-carboxylic acid
  参考文献：
  名称：

  取代吡唑-4-羧酸的合成及降血糖评价。

  摘要：

  描述了一系列取代的吡唑-4-羧酸作为降血糖药的合成和体内活性。与二甲双胍相比，一些有效化合物的模型化提供了某些类比，可以用来预测某些新型抗糖尿病药的设计。

  DOI：

  10.1016/s0960-894x(02)00380-3
• 作为产物：
  描述：

  ethyl 1-acetyl-3-hydroxy-1H-pyrazole-4-carboxylate 、 alkaline earth salt of/the/ methylsulfuric acid 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 20.5h， 以90%的产率得到ethyl 3-(benzyloxy)-1H-pyrazole-4-carboxylate
  参考文献：
  名称：

  取代吡唑-4-羧酸的合成及降血糖评价。

  摘要：

  描述了一系列取代的吡唑-4-羧酸作为降血糖药的合成和体内活性。与二甲双胍相比，一些有效化合物的模型化提供了某些类比，可以用来预测某些新型抗糖尿病药的设计。

  DOI：

  10.1016/s0960-894x(02)00380-3

文献信息

• AMINOPYRIMIDINE COMPOUND
  申请人：Cardurion Pharmaceuticals, LLC

  公开号：US20200095240A1

  公开（公告）日：2020-03-26

  The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

  本发明提供了一种具有CaMKII抑制作用的化合物，预计可用作心脏疾病（特别是儿茶酚胺多形性室性心动过速、术后心房颤动、心力衰竭、致命性心律失常等）的预防或治疗药物。本发明涉及一种由以下公式（I）表示的化合物：其中每个符号如规范中所定义，或其盐。
• 5-MEMBERED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES
  申请人：Shimizu Kazuo

  公开号：US20100227864A1

  公开（公告）日：2010-09-09

  The present invention provides compounds useful as agents for the prevention or treatment of a disease associated with abnormal serum uric acid level which has a uricosuric activity or the like. The present invention relates to 5-membered heterocyclic derivatives represented by the following general formula (I) having xanthine oxidase inhibitory activities and useful as agents for the prevention or treatment of a disease associated with abnormality of serum uric acid level, prodrugs thereof, or salts thereof. In the formula (I), T represents nitro, cyano and the like; ring J represents aryl or heteroaryl; Q represents carboxy, 5-tetazolyl and the like; Y represents H, OH, NH 2 , halogen, haloalkyl and the like; X 1 and X 2 independently represent CR 2 or N; R 2 represents H, alkyl and the like; R 1 represents halogen, cyano, haloalkyl, A-D-E-G-L-M, -N(-D-L-M) 2 and the like, in the formula, A represents a single bond, O, S and the like; D, G and M independently represent optionally substituted alkylene, cycloalkylene, heterocycloalkylene, arylene, heteroarylene and the like; E and L independently represent a single bond, O, S, COO, SO 2 and the like.

  本发明提供了一种化合物，其具有尿酸排泄活性或类似活性，可用作预防或治疗与异常血清尿酸水平相关的疾病的药剂。本发明涉及以下通式（I）表示的具有黄嘌呤氧化酶抑制活性的5-成员杂环衍生物，其可用作预防或治疗与血清尿酸水平异常相关的疾病的药剂、其前药或其盐。在公式（I）中，T表示硝基、氰基等；环J表示芳基或杂芳基；Q表示羧基、5-四唑基等；Y表示H、OH、NH2、卤素、卤代烷基等；X1和X2独立地表示CR2或N；R2表示H、烷基等；R1表示卤素、氰基、卤代烷基、A-D-E-G-L-M、-N（-D-L-M）2等，在公式中，A表示单键、O、S等；D、G和M独立地表示可选取代的烷基、环烷基、杂环烷基、芳基、杂芳基等；E和L独立地表示单键、O、S、COO、SO2等。
• 5-MEMBERED NITROGEN CONTAINING HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
  申请人：Shimizu Kazuo

  公开号：US20120289506A1

  公开（公告）日：2012-11-15

  5-membered heterocyclic derivatives represented by general formula (I) having xanthine oxidase inhibitory activities and useful as agents for the prevention or treatment of a disease associated with abnormality of serum uric acid level, prodrugs thereof, or salts thereof. In the formula (I), T represents nitro, cyano and the like; ring J represents aryl or heteroaryl; Q represents carboxy, 5-tetazolyl and the like; Y represents H, OH, NH 2 , halogen, haloalkyl and the like; X 1 and X 2 independently represent CR 2 or N; R 2 represents H, alkyl and the like; R 1 represents halogen, cyano, haloalkyl, A-D-E-G-L-M, —N(-D-L-M) 2 and the like, A represents a single bond, O, S and the like; D, G and M independently represent optionally substituted alkylene, cycloalkylene, heterocycloalkylene, arylene, heteroarylene and the like; E and L independently represent a single bond, O, S, COO, SO 2 and the like.

  通式（I）所表示的5元杂环衍生物具有黄嘌呤氧化酶抑制活性，并且可作为预防或治疗与血清尿酸水平异常相关的疾病的药剂，其前药或盐。在公式（I）中，T表示硝基，氰基等；环J表示芳基或杂芳基；Q表示羧基，5-四唑基等；Y表示H，OH，NH2，卤素，卤代烷基等；X1和X2独立地表示CR2或N；R2表示H，烷基等；R1表示卤素，氰基，卤代烷基，A-D-E-G-L-M，-N（-D-L-M）2等，其中A表示单键，O，S等；D，G和M分别表示可选取代的烷基，环烷基，杂环烷基，芳基，杂芳基等；E和L独立地表示单键，O，S，COO，SO2等。
• 5-membered nitrogen containing heterocyclic derivatives and pharmaceutical compositions comprising the same
  申请人：Kissei Pharmaceutical Co., Ltd.

  公开号：US08227500B2

  公开（公告）日：2012-07-24

  The present invention provides compounds useful as agents for the prevention or treatment of a disease associated with abnormal serum uric acid level which has a uricosuric activity or the like. The present invention relates to 5-membered heterocyclic derivatives represented by the following general formula (I) having xanthine oxidase inhibitory activities and useful as agents for the prevention or treatment of a disease associated with abnormality of serum uric acid level, prodrugs thereof, or salts thereof. In the formula (I), T represents nitro, cyano and the like; ring J represents aryl or heteroaryl; Q represents carboxy, 5-tetazolyl and the like; Y represents H, OH, NH2, halogen, haloalkyl and the like; X1 and X2 independently represent CR2 or N; R2 represents H, alkyl and the like; R1 represents halogen, cyano, haloalkyl, A-D-E-G-L-M, -N(-D-L-M)2 and the like, in the formula, A represents a single bond, O, S and the like; D, G and M independently represent optionally substituted alkylene, cycloalkylene, heterocycloalkylene, arylene, heteroarylene and the like; E and L independently represent a single bond, O, S, COO, SO2 and the like.

  本发明提供了化合物，其具有尿酸排泄活性或类似活性，可用作预防或治疗与异常血清尿酸水平相关的疾病的药剂。本发明涉及下式（I）表示的5-成员杂环衍生物，其具有黄嘌呤氧化酶抑制活性，并可用作预防或治疗与血清尿酸水平异常相关的疾病的药剂，其前体药物或其盐。在公式（I）中，T表示硝基，氰基等；环J表示芳基或杂芳基；Q表示羧基，5-四唑基等；Y表示H，OH，NH2，卤素，卤代烷基等；X1和X2独立地表示CR2或N；R2表示H，烷基等；R1表示卤素，氰基，卤代烷基，A-D-E-G-L-M，-N（-D-L-M）2等，在公式中，A表示单键，O，S等；D，G和M独立地表示可选取代的烷基，环烷基，杂环烷基，芳基，杂芳基等；E和L独立地表示单键，O，S，COO，SO2等。
• Aminopyrimidine compound
  申请人：Cardurion Pharmaceuticals, LLC

  公开号：US11130752B2

  公开（公告）日：2021-09-28

  The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

  本发明提供了一种具有 CaMKII 抑制作用的化合物，该化合物有望用作预防或治疗心脏疾病（特别是儿茶酚胺能多形性室性心动过速、术后心房颤动、心力衰竭、致命性心律失常）等的药物。 本发明涉及一种由式（I）代表的化合物： 其中各符号如说明书中所定义，或其盐类。